After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program

Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech.